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This report introduces some aspects of our current basic research Focus on the unique metabolic pathways within the
melanocyte. Using this approach, we hope to gain a better understanding of the pathophysiology of malignant melanoma
and develop early laboratory diagnostic tests for this disease. Specifically, we will discuss that 1) the synthesis of
pheomelanin is markedly increased in malignant melanoma and dysplastic melanocytic nevi; 2) high levels of metabolites of
pheomelanin and eumelanin can be detected in the urine and blood of patients with metastasic melanoma; 3) this release of
melanin metabolites appears to correlate with tumor thickness and tumor load, including the extent of metastasis; 4) the
synthesis of melanosomal proteins also becomes aberrant in malignant melanoma; and 5) this abnormal me-lanosome
synthesis can be utilized in the identification of antigenic epitopes that are uniquely expressed in malignant melanoma. We
believe that this synthesis and secretion of abnormal melanin pigment and melanosomal proteins (human melanosome-
specific antigen) would be useful for the development of early laboratory diagnostic and monitoring tools for malignant
melanoma. In addition, we also report the detection of pheomelanin component in ‘‘normal’’ unex-posed skin; however, the
relative amount of pheomelanin in the skin does not reflect hair color (e.g., red hair). The nature of this pheomelanin
component in the skin needs to be further clarified. J Invest Dermatol 100:259S–268S, 1993
The melanocyte is a cell of neural crest origin that specializes in the
production of melanin pigments. This capability resides within the
melanosomes, which are membrane-bound organelles. Through den-
dritic extensions of the melanocyte, they are transferred to keratinocytes,
resulting in pigmentation of the skin. The role of melanin pigmentation in
the skin is still not well understood, although one of its major functions is
obviously the protection of the skin from harmful environmental effects
(e.g., ultraviolet radiation [UVR]) [1].
The melanoma cell is the malignant counterpart of the melanocyte.
As such, it is characterized by anaplasia, rapid growth rate, invasion of
local tissue, and propensity for metastasis. In the past, the concepts of
melanocytic differentiation and malignant transformation were largely
based on morphologic observations [2]. This has important clinical
implications because the level and depth of invasion correlate directly
with the potential for metastases and long-term patient survival [3];
however, recent advances in analytical chemistry and the development
of the monoclonal antibody technique have enabled researchers to better
define the biochemical and molecular dynamics of tumor progression
(e.g., the expression of specific cellular antigens at each stage of
transformation) [4,5].
The theory of oncogenesis postulates that the derangement(s) in the
control and regulation of certain genes, termed ‘‘oncogenes,’’ results in
tumorigenicity. Depending on where the mutational change occurs, the
transformed cell may lose its capability to differentiate and/or synthesize
certain proteins involved in cellular proliferation and differentiation.
Alternatively, it may overproduce proteins that are normally suppressed
by the differentiated cells [6]. More specifically, aberrant control of the
components of signal-transduction pathways or nuclear transcription
factors in the melanocyte may ultimately be reflected as a dysfunction or
derangement in melanogenesis. These gene products may then be
expressed as unique differentiation markers within the cytoplasm or on
the cell surface of these transformed cells. Once the carcinogenic insult
has occurred, karyotypic, genetic, and epigenetic instability may lead
to tumor promotion and progression; this has been termed the
‘‘mutagenesis cascade’’ [4]. This in turn may lead to the selection and
propagation of new subpopulations of tumor cells with enhanced
proliferative and metastatic capability [6]. The loss or gain in certain
antigenic markers may reflect this dynamic phenomenon and resultant
tumor heterogeneity.
By studying the derangements in the metabolic machinery that
characterizes the transformed melanocyte, we hope to gain a better
understanding of the biology of malignant melanoma. The biologic
uniqueness of the melanocyte differentiation resides in its tendency
to retain the biochemical apparatus for the conversion of tyro-
sine to melanin in its highly specialized organelle, the melanosome.
It contains at least 15–20 proteins [7,8], in addition to tyrosinase and
melanins (Fig 1). This differentiated morphologic and biochemical
property is unique to the melanocyte and is markedly altered in
its malignant counterpart. These changes include abnormalities in
matrix protein substructures of melanosomes as well as the degree
and type of melanin depositions. This report introduces our current
research, which focuses on the altered synthesis of melanin and
melanosomal proteins and their abnormal degradation in malignant
melanoma.
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MELANIN SYNTHESIS IN NORMAL AND
NEOPLASTIC MELANOCYTES
Synthesis of Pheomelanin and Eumelanin in Skin, Hair, Nevi, and
Melanoma Two basic classes of melanin pigments are synthesized in
mammals: eumelanin and pheomelanin. The classification of the two
types of pigments had been based largely on the color, solubility
properties, and sulfur content of isolated melanin [8]. Eumelanin is a
dark brown to black pigment that is insoluble in acid and alkali and
contains nitrogen (6–9%) but no sulfur (0–1%). On the other hand,
pheomelanin is a reddish-yellow pigment that is soluble in alkali and
possesses both nitrogen (8–11%) and sulfur (9–12%). However, the color
and solubility properties are by no means reliable and quantitative.
Isolation of melanin is required to analyze its elemental composition [9].
Furthermore, the sulfur in isolated melanin is not necessarily derived
from pheomelanin [8,10].
We recently developed a simple, rapid method for the quantitative
analysis of eumelanin and pheomelanin in tissues that makes the
isolation of melanin unnecessary. The method is based on the formation
of pyrrole-2,3,5-tricarboxylic acid (PTCA) by permanganate oxidation
and of aminohydroxyphenylalanine (AHP) isomers by hydriodic acid
hydrolysis. The products are determined by high-performance liquid
chromatography (HPLC) [11]. With this chemical method, we were
able to demonstrate that red and blond hair contain more pheo-
melanin component than either brown or black hair [12], but it is not
clear as to what melanogenesis type occurs in the skin and whether
the melanogenesis in the skin has any relationship to that of the hair
follicles.
Eumelanin and Pheomelanin Pigments in the Hair and Skin: Table I
summarizes the content of pheomelanin and eumelanin components, as
determined by the measurement of PTCA and AHP in hair follicles. Hair
follicles show a clear correlation between hair color (black, yellow, and
white) and the amount of AHP (pheomelanin) and PTCA (eumelanin). The
natural pheomelanic yellow hair follicles contain more than 600 times the
pheomelanic component compared with that of eumelanic black hair
follicles. It is important to note, however, that albino hair follicles, which do
not have any melanin pigments, reveal mean AHP and PTCA values of 15
and 2.0ng/mg of tissue, respectively. In addition, control normal tissues,
such as liver, kidney, and brain, also reveal some AHP and PTCA values,
ranging from 0.6 to 1.4ng/mg of tissue. Thus, this AHP-PTCA measurement
method always detects some intrinsic non-melanin pigments; however, if
the AHP-PTCA values are high, they would be fairly accurate and
representative of the amount of melanin pigments in tissues.
Pheomelanin and Eumelanin Pigments in Human Hair Follicles of
Various Color Types and Ethnic Backgrounds: Because human red hair
follicles reveal a fairly high value of AHP, these values should correlate
with the actual amount of the pheomelanin in tissues. Indeed, the value
of the AHP/PTCA ratio corresponds well to the differences in hair color
(e.g., AHP and PTCA values are 4.8–5.1 and 100–200ng/mg of tissue,
respectively, in black hair follicles, whereas they are 15–30 and
1.0–5.0 ng/mg of tissue in red hair follicles) (Table II). On the other
hand, when we compare the amount of melanin pigments in human skin
Figure 1. Melanin synthesis pathway within the melanocyte. Both eumelanin and pheomelanin pigments are synthesized from the common metabolic pathway
(i.e., conversion of tyrosine to dopa and dopaquinone in the presence of tyrosinase). 5-6-Dihydroxyindole (5,6DHI), its carboxylic acid form (5,6DHI2C), and
5-S-cysteinyldopa are the major metabolites of eumelanin and pheomelanin synthesis. 5,6DHI2C is subsequently O-methylated to form 5(6)-hydroxy-6(5)-
methoxyindole-2-carboxylic acid [5(6)H6(5)MI2C].
Table I. Content and Type (Pheomelanin and
Eumelanin) of Melanin Pigment in Hair and Skin,









Black (C57B1, a/a) (3)b 53±32 1090±160 0.048
Yellow
(C57B1, Ay/a) (3) 2930±310 4.4±1.1 665
Albino (KK, c/c) (3) 15±8 2.3±1.2 6.5
Human skin (white)a
Blond-brown (2) 11.7±0.7 0.8±1.4 19.3±8.9
Blond (7) 3.5±1.3 0.5±0.4 8.5±3.3
Brown (1) 3.8 0.9 4.4
Red (4) 2.3±0.7 0.5±0.1 5.9±3.8
Control normal tissuea
Liver (C57B1 mouse) (1) 0.7 0.6 —
Kidney (C57B1 mouse) (1) 1.4 0.6 —
Brain (C57B1 mouse) (1) 1.0 0.6 —
aData previously reported by Jimbow et al [12], Ito and Fujita [56], and
Salopek et al [13].
bNumbers in parentheses are the number of samples examined.
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with various hair color types, there is no clear relationship between
the value of AHP in the skin and the hair color type (Table I). If the
melanogenesis type were the same in the hair follicles and skin, then
one would expect to find a descending AHP/PTCA ratio for normal
skin specimens taken from red to blond and blond to brown and then
to black-haired individuals, respectively. This was not the case in our
previous study [13]. Again, all the PTCA values in the hair follicles
with different hair color types are found to be relatively low, ranging from
0.5 to 1.3 ng/mg of tissue. Because pure albino hair follicles showed
PTCA values close to 2.3 ng/mg of tissue, all of these low PTCA values in
the skin may not represent the actual amount of the eumelanin
component. The PTCA measurement is lower than the actual amount
of eumelanin inasmuch as one can see a fairly large number of
melanosomes under an electron microscopy or argylophilic eumelanin
pigment at light microscopy with silver stain within the skin. This reading
of low PTCA values in the skin may come from the inherent low
sensitivity of eumelanin and PTCA measurement because eumelanin is to
a large extent insoluble in the solvents. In addition, there is some
difficulty in the measurement of PTCA values, which depend on the the
tissue type such as skin. Also, all of the PTCA values (nanograms/
milligrams of tissue) are expressed by a 50 times multiplication of the
obtained PTCA values, and this magnifies any small variation in
eumelanin content. Nonetheless, it is important to note that normal
human skin contains a significant amount of pheomelanin component.
This finding contradicts the previously held concept that normal skin
from all ethnic backgrounds and different colorations does not have any
pheomelanin component.
Pheomelanin and Eumelanin Pigments in Melanocytic Nevi and
Malignant Melanoma: Table III shows the contents of pheomelanin and
eumelanin in culture cells of metastatic human melanoma (ng/107 cells)
and tissues of murine melanoma and human melanocytic nevi. Similar to
our previous reports [8,13], both melanoma and nevus tissues (cells)
contain a high amount of AHP (pheomelanin component). The
production of pheomelanin per milligram of tissue, or per 107 cells, is
increased significantly in melanoma and melanocytic nevi compared
with normal skin. In addition, there appears a trend of increased
production of pheomelanin from normal skin to common melanocytic
nevi, then to dysplastic melanocytic nevi, and, finally, to malignant
melanoma. Of note there was a much higher content of pheomelanin
component in dysplastic nevi compared with benign, common melano-
cytic nevi in the same patients [13]. The nature of increased production
of pheomelanin component in neoplastic conditions is not yet clear;
however, there is considerable evidence that suggests that pheomelanin
and/or its precursors play an important role in carcinogenesis/mutagen-
esis. Erhlich ascites carcinoma cells were found to be more susceptible to
Table II. Hair Color and Content of Pheomelanin (AHP) and Eumelanin (PTCA) in Hair Samples from Different
Ethnic Originsa
Subject Number Hair Color AHP (ng/ml) PTCA (ng/ml) AHP/PTCA Ethnic Origin
1 Blond-brown 3.3 8.1 0.41 100% Norwegian
2 Blond-brown 3.0 9.6 0.31 50% German, 50% Norwegian
3 Blond-brown 2.7 16.5 0.16 100% German
4 Light brown 2.1 12.6 0.17 50% Hungarian, 50% German
5 Blond, faint red 2.7 8.7 0.31 50% English, 50% Norwegian
6 Blond, slight red 9.6 8.1 1.19 50% English, 25% German, 12.5% Welsh, 12.5% French
7 Blond, slight red 9.3 7.2 1.29 100% Norwegian
8 Medium light brown 1.8 42 0.43 100% German
9 Medium light brown 2.4 18.3 0.13 50% Norwegian, 25% Polish, 25% German
10 Medium light brown 1.5 42 0.04 50% Irish, 25% Dutch, 25% German
11 Fire red 15.3 11.4 1.34 25% Irish, 25% Scottish, 50% Swedish
12 Fire red 51 6.9 7.39 25% Irish, 25% Swedish, 25% Czechoslovakian, 25% German
13 Fire red 36 6.9 5.22 25% Irish, 25% Swedish, 25% Czechoslovakian, 25% German
14 Light Red 18.9 28.5 0.66 25% Dutch, 25% German, 50% Scottish
15 Light red 13.2 9.0 1.47 50% Swiss, 25% Danish, 25% English, 25% German
16 Light red 54 13.5 4.0 25% Irish, 25% Swedish, 25% Czechoslovakian, 25% German
17 Dark red 6.0 16.5 0.36 50% Norwegian, 50% Bohemian
18 Medium dark brown 2.7 25.5 0.11 50% Polish, 50% French
19 Dark brown 4.8 42 0.11 50% German, 25% English, 25% Norwegian
20 Black 4.8 114 0.04 50% Inca, 50% Spanish
21 Dark brown 1.5 39 0.04 50% German, 25% Welsh, 25% Irish
22 Black 4.8 114 0.04 50% Inca, 50% Spanish
23 Black 4.8 201 0.02 100% Japanese
24 Black 5.1 111 0.05 100% Japanese
aA hair sample (30mg) was processed for AHP (pheomelanin) and PTCA (eumelanin) measurement. These data are recalculated from our previous report
[57], which expressed the melanin content as a percentage in weight of melanin/weight of wet tissue.
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the harmful effects of the pheomelanin than eumelanin after exposure to
ultraviolet radiation (UVR). They demonstrated greater impairment in cell
growth and increased susceptibility to cell lysis [14]. Using the reversion
test of Ames, Harsanyi et al [15] reported that UV-irradiated pheome-
lanin can induce mutagenesis. More recently, it was shown that
cysteinyldopa, a pheomelanin precursor, is photochemically unstable
in the presence of environmentally relevant UVR (i.e., UVB) [16].
Cysteinyldopa was found to bind to calf thymus DNA with UVB
activation and induced single-strand DNA breakage. The mechanism by
which pheomelanin exerts its cytotoxic effect is poorly understood.
Pheomelanin on UVR exposure has been shown to generate reactive
oxygen species (primarily superoxide radicals) [17] and to increase the
free radical content of melanin [18]. It is postulated that the creation of
such photodegra-dation products accounts for the photobiologic effects
of pheomelanin.
On the basis of our electron microscopic findings, we previously
hypothesized that dysplastic melanocytic nevus lesions contain an
increased amount of phototoxic pheomelanin [19]. Supporting data
(Table III) lead us to believe that these observations may account for the
tendency of some dysplastic melanocytic nevi to undergo malignant
transformation. The observed increase in pheomelanin versus eumelanin
is unlikely to be the only factor involved in the carcinogenesis of
dysplastic melanocytic nevi. Fibroblasts and Epstein-Barr virus –
transformed lymphoblastoid cells from familial dysplastic nevus syn-
drome patients, which do not contain any pigment, demonstrate
increased sensitivity to UVR and to the UV-mimetic 4-nitro or quinone
1-oxide [20,21]. Because dysplastic nevi and malignant melanoma occur
frequently on a familial basis, we speculate that the inherent suscept-
ibility of melanocytes to UVR, along with the formation of photoreactive
pheomelanin or its precursors, plays a major role in the underlying
process of melanocytic progression to malignant melanoma. This
hypothesis may have particular relevance to the development of
melanoma in the familial dysplastic nevus syndrome. Following the
same line of reasoning, the dysplastic melanocytes may be programmed
to be highly susceptible to UVR and produce abnormal melanin pigment
and pheomelanin, which can act synergistically to promote the
transformation of the melanocyte [22].
Release of Pheomelanin and Eumelanin Metabolites in the Urine and
Serum of Melanoma Patients Melanoma patients in advanced stages are
known to excrete large quantities of melanin metabolites in their urine.
This is termed melanuria or melanogenuria, which means elevated
excretion of melanogens in the urine [23]. The following melanin
precursors or metabolites can be expected to be seen in the urine and in
the plasma of melanoma patients.
Dihydroxyphenylalanine (Dopa) and Its Derivatives: In patients with
metastatic malignant melanoma, dopa can be expected to be released
from the tumor sites. There are several reports indicating that quantitation
of dopa in the urine may be of value in the diagnosis of melanoma
metastases. Similarly, plasma dopa may also be increased in some
patients with advanced melanoma metastases [24–26]. Dopa itself has a
very low plasma clearance because it is decarboxylated in the kidney
[27]. In addition, determination of urine levels of dopa has limited
diagnostic value in only advanced stages of melanoma [28]. Instead,
quantitation of the urinary excretion of the dopa metabolites, dopamine,
and their methylated products, methoxy-tyrosine and homovanillic acid,
can be used to measure dopa turnover [29].
In fact, we described a method for determining the ‘‘total’’ excretion
of acidic metabolites of catecholamines by measuring 3,4-dihydrox-
yphenylacetic acid (Dopac) formed by hydriodic acid hydrolysis of
4-hydroxy-3-methoxyphenylacetic acid, 4-hydroxy-3-methoxymandelic
acid, and their conjugates. The Dopac in the diluted hydrolysate is
measured directly by liquid chromatography with electrochemical
detection. Normal values, expressed in relation to excretion of creatinine,
vary as a function of age. For healthy subjects, the mean Dopac value
after hydrolysis was 1.15 times that for unconjugated homovanillic acid,
4-hydroxy-3-methoxymandelic, and Dopac combined. Our results
indicated the potential usefulness of acidic metabolites of catechola-
mines for diagnosis and prognosis of patients with melanoma and other
neural crest tumors that produce dopa or catecholamines [30].
5-S-Cysteinyldopa: The urinary excretion of 5-S-cysteinyldopa is
increased in most patients with disseminated melanoma [31]. As a rule,
this increase appears at about the same time as clinical signs of metastasis
become evident, but it may precede symptoms by several months. On the
other hand, some patients, especially those with amelanotic melanoma
metastases, may show normal excretion values despite disseminated
disease [32].
The current consensus for the diagnostic value of 5-S-cysteinyldopa is
that the plasma, as opposed to urine levels of 5-S-cysteinyldopa may be
an important tool for identifying melanoma at an earlier, more treatable
Table III. Contents of Pheomelanin (AHP) and Eumelanin (PTCA) in Malignant Melanoma and Melanocytic Nevi
Tissue (n) AHP (ng/mg) PTCA (ng/mg) AHP/PTCA
Mouse melanoma
B16 melanosome (lyophilized) (1) 68 1530 0.4
Harding Passey melanosome (1) 260 800 0.3
B16 melanoma/tissues (3) 8.9±1.3 106±59 0.08
Harding Passey tissues (3) 51±5.9 16±4.7 3.4
Human melanoma (ng/107 cells)
SKMEL 23 culture cells (4) 1656.3±101.5 278.3±89.7 6.5±2.5
G361 culture cells (3) 1112.3±186.2 20.2±4.4 55.9±6.0
Human dysplastic nevia
Familial dysplastic nevus syndrome patients (6) 67.7±82.9 0.8±0.4 121.6±178.6
Overall dysplastic nevus sample population (19)b 47.5±48.6 1.3±1.4 84.8±108.8
Human common melanocytic nevia (clinically and histologically) (16) 34.5±33.3 2.3±2.4 25.0±29.7
aData from previous study by Salopek et al [13].
bIncludes both familial and sporadic non-familial forms of dysplastic nevi.
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stage. In addition, it may be used for monitoring patients at risk for the
development of metastatic melanoma (e.g., those with dysplastic nevus
syndrome) [33]. Those with localized cutaneous malignant melanoma
and no distant metastases had 5-S-cysteinyldopa levels two times greater
than those of control subjects, whereas the levels of those with regional
lymph node involvement were four times greater than those of control
subjects. Levels of those with extraregional metastases were seven
to 450 times higher than those of control subjects. Moreover, plasma
5-S-cysteinyldopa levels correlated with the spread of disease and
were useful in distinguishing primary melanoma and advanced-stage
melanoma.
Indolic Compounds: Several indole derivatives have been found in the
urine of patients with metastatic melanoma. Two Thorma¨hlen-positive
compounds have been identified as the glucuronides of 5-hydroxy-
5-methoxyindole and its isomer 6-hydroxy-5-methoxyindole in the
urine from melanoma patients. Both compounds are methylated products
of 5,6-dihydroxyindole [34]. Because catechol-O-methyl transferase
catalyzes methylation of 5,6-dihydroxyindole primarily at position 6,
whereas hydroxyindole-O-methyl transferase catalyses methylation of
5,6-dihydroxyindole mainly at position 5, the methylation of these
compounds can be attributed to the activity of catechol-O-methyl
transferase. In another study on the urine from a patient with widespread
melanoma metastases, 5-hydroxy-6-methoxyindole-2-carboxylic acid
(5H6MI2C) and its isomer 6-hydroxy-5-methoxyindole-2-carboxylic acid
(6H5MI2C) were demonstrated by gas chromatography/mass spectro-
scopy [36]. Both compounds are methylated products of 5,6-dihydrox-
yindole-2-carboxylic acid.
High Plasma Level ofEumelanin Precursor 6-Hydroxy-5-Methoxyindole-
2-Carboxylic Acid as a New Prognostic Marker for Human Malignant
Melanoma: To establish a better method for the detection of occult
melanoma, we recently carried out an HPLC measurement of 5-S-
cysteinyldopa, 5H6MI2C, and 6H5MI2C in the plasma of melanoma
patients and correlated it with melanoma prognosis. We found that 1) the
peak of 5H6MI2C is often masked by that of solvents; thus its
measurement may be unreliable; 2) the normal plasma level of 5-S-
cysteinyldopa and 6H5MI2C is less than 2.28 and 1.14 ng/ml,
respectively; 3) the group with normal 5-S-cysteinyldopa and 6H5MI2C
plasma levels does not have any detectable metastases; 4) the group with
an abnormal level of either high 5-S-cysteinyldopa (42.28) and low
6H5MI2C (o 1.14) or low 5-S-cysteinyldopa (o2.28) and high
6H5MI2C (4 1.14) is also disease free, but tumor thickness of primary
melanoma tends to be more than 2.00mm, indicating this group to be at
Table IV. Serum Levels of 5-S-Cysteinyldopa (5-S-CD) and 6-Hydroxy-5-Methoxyindole-2-Carboxylic Acid
(6H5MI2C) in Subjects With and Without Melanoma
5-S-CD 6H5MI2C
Patient Group (n) Serum Levela p Value Serum Levela p Value
Normal, healthy subject (13) 1.17±0.51 — 0.51±0.53 —
Metastatic non-melanoma cancers (10) 2.15±0.47 NS 0.56±0.36 NS
Melanoma with no metastasis (26) 3.37±2.58 po0.1 1.63±2.55 po0.01
Past history of metastatic melanoma (24) 2.65±1.62 po0.05 1.81±1.67 po0.02
Melanoma with metastasis (8) 6.47±4.42 po 0.001 5.98±6.14 po0.001
ang/ml of plasma sample.











1 IgG1, k Human melanoma (metastatic) Melanosome DE 52
b 48/53 (gp)  + +
Non-melanin binding (Amelanotic cells)
2 IgG1, k Human melanoma (metastatic) Melanosome DE 52
b 42/60 (gp)  + +
Non-melanin binding (Amelanotic cells)
3 IgM, k Human melanoma (metastatic) Melanosome DE 52b 40/45/64  + +
Non-melanin binding (Melanotic and amelanotic cells)
4 IgM, k Human melanoma (metastatic) Melanosome DE 52b 45/64  + +
(Both amelanotic and melanotic cells)
5 IgG1, k Human melanocyte Melanosome DE 52
b 69 (gp) + + +
(TPAc-stimulated) Melanin binding (Only melanotic cells)
6 IgG1, k Human melanoma (SK MEL 23) Melanosome DE 52
b 41/22/17/11  + +
Melanin binding (Amelanotic cells)
aMolecular weight.
bIsolated from DE 52 ionic-exchange chromatography with a linear gradient of KCL (0–0.25M).
c12-O-terradecaxoyl-phorbol-13-acetate.
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a higher risk for metastases; and 5) the group with abnormal level of both
5-S-cysteinyldopa and 6H5MI2C shows the presence of metastases at the
time of sampling or within 3–4 months of follow-up. Therefore, plasma
5-S-cysteinyldopa and 6H5MI2C measurement provides an additional
method for estimating melanoma prognosis, with 6H5MI2C plasma level
a much better indicator than that of 5-S-cysteinyldopa (Table IV) [35,36].
Of note, we would be able to detect high-risk patients with melanoma
from the serum levels of these melanin metabolites. In the past, we have
determined by HPLC analysis a number of patients with melanoma with
‘‘hidden’’ metastases that were not detectable by conventional screening
methods. This HPLC method, however, takes time and requires the use of
specific equipment. Similar results were recently reported in experi-
mental animal models using B16 melanoma-bearing mice; however,
under the experimental conditions, both eumelanin and pheomelanin
precursors in plasma levels were of equal value in estimating the degree
of melanoma growth [37].
SYNTHESIS OF MELANOSOMAL PROTEINS IN
NORMAL AND MALIGNANT MELANOCYTES
Unique Expression of Melanosomal Proteins in Normal Melanocytes and
Malignant Melanoma In many genetic and neo-plastic disorders that
exhibit abnormal melanin pigmentation, the melanosomes change in
size, develop peculiar substructure, and show disorientation of structural
components [19]. This alteration involves matrix substructures as well as
the degree and manner of melanin depositions [22]. To further address
the relationship between the alteration in the synthesis of the
melanosomal proteins and melanocyte transformation, a series of murine
monoclonal antibodies (MoAbs) were developed in our laboratory
against human melanosome-specific antigens (HMSAs). They can be
briefly summarized as follows (Table V).
HMSA-1 and HMSA-2: HMSA-1 and HMSA-2 are present only in
neoplastic epidermal melanocytes and are absent in normal epidermal
melanocytes of the skin and hair follicles. They are highly expressed
in superficial spreading melanoma and nodular melanoma as well as
acral lentiginous melanoma (475% expression) [38]. In contrast,
HMSA-1 and HMSA-2 are least expressed in the lentigo maligna
melanoma (o 10%). Of note, HMSA-1 and HMSA-2 are not expressed
in epidermal melanocytes (including epidermal nevocytic melanocytes)
of benign common melanocytic nevi, whereas they are highly and
heterogeneously expressed in epidermal melanocytes in the lesion of
dysplastic nevi [39]. Of interest, MoAbs HMSA-1 and HMSA-2 would be
capable of delineating two types of dysplastic melanocytic nevi, possibly
through different epitope expression of the same antigen in the epidermis.
It is concluded that the characterization of HMSA-1 and HMSA-2
expression would be useful in predicting malignant transformation of
melanocytes [40].
HMSA-3 and HMSA-4: Similar to HMSA-1 and HMSA-2, HMSA-3 and
HMSA-4 are identifiable on routine paraffin sections. Again, they identify
only neoplastic melanocytes, not normal melanocytes in the epidermis.
Therefore, a detailed comparison of four MoAbs was made in four major
subtypes of malignant melanoma; acral lentiginous melanoma, super-
ficial spreading melanoma, lentigo maligna melanoma, and nodular
melanoma. In all cases of primary melanoma studied, one of the four
MoAbs always showed a positive reactivity, even though the other three
were negative or weakly positive [41]. Our immunohistopathologic study
indicated that HMSA provides a unique marker to identify malignant
melanoma cells and may be even useful to delineate the subtypes of
malignant melanoma with the HMSA expression [40].
HMSA-5 and HMSA-6: In addition to HMSA-1 -HMSA-4, we developed
two new murine monoclonal MoAbs (i.e., HMSA-5 and HMSA-6), and
both are again reactive with melanocytes on routine paraffin sections.
HMSA-5 is seen in both normal and neoplastic melanocytes in the
epidermis [42,43]. Both react with 12-O-tetra-decaxoyl-phorbol-13-
acetate-stimulated melanocytes [44]. MoAb HMSA-5 reacts strongly
with normal melanocytes, pigmented cells of common melanocytic nevi
and dysplastic melanocytic nevi, and melanoma cells of superficial
spreading melanoma and nodular melanoma. In contrast to HMSA-1 and
HMSA-2, HMSA-5 is not detectable on immunohistochemistry once
these melanosomes are transferred to keratinocytes (Fig 2).
Different from HMSA-5, HMSA-6 reacts with normal and neoplastic
melanocytes. In our preliminary study, all 14 cultured metastatic human
melanoma cells tested revealed a positive reactivity with HMSA-6 in both
enzyme-linked immunosorbent assay and immunostaining assays using
the avidin – biotin complex technique. Of importance, three of five
neuroblastoma cell lines tested showed the expression of HMSA-6. This
HMSA-6 expression was, however, not seen in the two cultured cell lines
of human astrocytomas. It appears that HMSA-6 shares an antigenic
epitope common to other neural-crest-derived tumors [45].
Biosynthesis and Co-Translational and Post-Translational Regulation of
Melanosomal Glycoproteins The intracellular distribution of HMSA-1
was reported previously [46]. HMSA-1 is localized under immunoelec-
tron microscopy in the melanosomal matrix and in rough and smooth
endoplasmic reticulum but not in the Golgi complexes. HMSA-1 and
HMSA-2 display many similarities in tissue distribution but show some
differences on the surface expression by fluorescence-activated cell
sorter scan histogram study. The cell-surface expression of HMSA-1 and
HMSA-2 is 12% and 19%, respectively (Fig 3). The immunochemical
properties of MoAbs HMSA-3 and HMSA-4 have not been well
characterized because of their immunoglobulin (Ig) subtype of IgM;
however, they express the cell-surface labeling as much as 14% and
Figure 2. Comparison of immunohistochemical reactions of MoAb HMSA-1
and HMSA-5. (a)MoAb HMSA-1, showing a positive reaction with melanoma
cell nests in the epidermis and dermis of superificial spreading melanoma.
There is, however, no positive reaction with ‘‘normal’’ epidermal
melanocytes (magnification  160). (b) MoAb HMSA-5, showing positive
staining to ‘‘normal’’ melanocytes and melanoma cell nests in the epidermis
(magnification  160).
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34%, respectively. The intracellular distribution and co-translational and
post-translational glycosylation of HMSA-5 and HMSA-6 can be briefly
specified as follows.
Immunoelectron Microscopy Studies for Biodistribution:
HMSA-5. Under immunoelectron microscopy, the immunogold particles
that pick up the distribution of HMSA-5 are found in the cisternae of
Golgi complexes and around/within the melanosomes at various
maturation stages. Of note, HMSA-5 immunogold particles are not
directly associated with the melanosomal surface. Instead, they attach on
or adjacent to the microvesicles (approximately 40 nm in diameter) that
have been previously described as ‘‘vesicu-loglobular bodies’’ [47].
These bodies aggregate around the melanosomal membrane and are
often present within the melanosomal matrix. The HMSA-5 immunogold
particles are therefore, under a low-power view, localized around the
melanosomal surface as well as within the melanosomal matrix. They are
most prominent at early maturation stages of melanosomes (i.e., stages I
and II) but not at later stages of maturation (such as stage IV). The
immunogold particles are not seen on the surface of the inner matrix
lamellae (Fig 4, a–c).
HMSA-6. The biodistribution of HMSA-6 has been examined with an
indirect immunoperoxidase reaction using the avidin-bio-tin complex
method. The immunoprecipitate of HMSA-6 is identified within large
vacuoles, not the melanosomes at various maturation stages. It is,
however, not present on vesiculoglobular bodies nor on the Golgi
complexes, as seen with HMSA-5. Within the melanosomes, HMSA-6
immunoprecipitates are diffusely scattered on the matrix.
Co-Translational and Post-Translational Modification of Melanosomal
Glycosylation:
HMSA-5. Immunoprecipitation experiments using 125I-labeled cell
lysates pre-treated with the glycosylation inhibitor (monensin or
tunicamycin) demonstrated some differences in gel profiles. Monensin
causes an apparent increase in the amount of immunoprecipit-able
antigen compared with controls in both cell-surface and total labeled
cell lysates. This is followed by an increase in the relative molecular
mass (Mr) of immunoprecipitated antigen, indicating alterations in the
HMSA-5 molecule in the post-translational process. When tunicamycin
is used in the experiment, an opposite result is seen. There is a decrease
in the amount of immunoprecipitable antigen but without an accom-
panying downshift in the Mr on sodium dodecyl sulfate (SDS)-
polyacrylamide gel electrophoresis (PAGE). These results are reprodu-
cible in biosynthetic radiolabeling inhibitor experiments using
35S-methionine. Monensine again causes a slight decrease in the Mr of
HMSA-5 antigen and a quantitative increase in its amount. How-
ever, tunicamycin treatment does not immunoprecipitate any proteins
detectable by SDS – PAGE fluorography, suggesting a role for N-linked
saccharide residues in the formation or folding of the HMSA-5
epitope. To determine the degree of N-linked glycosylation of HMSA-
5, immunoprecipitates of mature, fully glycosylated HMSA-5 were
digested with N-gly-canase. Over the duration of the digestion
period, the Mr of HMSA-5 antigen decreased from 70 to 60 kDa. This
provides evidence that HMSA-5 contains 3-5 N-linked oligosaccharide
chains [44,45].
Murine MoAb TA99 detects a 70–75-kDa pigmentation-associated
antigen glycoprotein (gp 75) in human melanoma cell lines. The antigen
cannot be detected on the cell surface by sensitive rosetting techniques or
absorption studies, nor can it be detected as a secreted product in culture
fluids. Of importance, the gp 75 pep-tides and cDNA had an
approximate 90% homology with, respectively, the amino acid and
nucleotide sequences of a mouse gene that maps to the b (brown) locus.
This brown locus determines coat color of mice, indicating that the gp 75
derives from a melanosomal constituent and that it regulates or
influences the melanin synthesis [48,49].
Because of the similarity in the size and intracellular distribution,
comparison of HMSA-5 with gp 75 has been carried out. Sequential
immunoprecipitation with MoAb Mel-5/TA99 indicates that gp 75 and
Figure 3. Flow-cytomerric analysis of MoAb HMSA-1 -HMSA-6. Cell-surface expression of MoAb HMSA-1 -HMSA-6 antibodies was examined by using a F AC-
SCAN flow cytometer (Becton Dicksen, Ontario, Canada) with excitatory wavelength 488 nm. G361 melanoma cells were incubated with the corresponding
MoAb HMSA-1 -HMSA-6 for 1 h at 4 1C. After two washes with phosphate-buffered saline (PBS) containing 0.1% nonidet 40, goat anti-mouse immunoglubulins
G, A, and M labeled with fluorescein isothiocyanate were added and incubated for 30min at 4 1C. Final cells were washed twice with phosphate-buffered saline
and their fluorescence was analyzed, (a) Positive control with anti-GD3 MoAb, showing 80.39% of cell-surface labeling; (b) negative control with normal mouse
serum, showing 4.66% of cell-surface labeling; (c) MoAb HMSA-1 with G361 cells, showing 12.09% of cell-surface labeling; (d) MoAb HMSA-2 with G361
cells, showing 19.38% of cell-surface labeling; (e)MoAb HMSA-5 with G361 cells, showing 14.10% of cell-surface labeling; (f)MoAb HMSA-4 with G361 cells,
showing 34.75% of cell-surface labeling; (g) MoAb HMSA-5 with G361 cells, showing 3.24% of cell-surface labeling; and (h) MoAb HMSA-6 with G361 cells,
showing 2.95% of cell-surface labeling.
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HMSA-5 recognize the antigen with the same size. In addition, the
trypsin cleavage of gp 75 and HMSA-5 immunoprecipitates showed
identical SDS-PAGE patterns, confirming the identity of the two
molecules. However, immunohistochemical studies showed several
different features between HMSA-5 and gp 75, indicating that the two
probably recognize the different epitopes of the same glyco-
protein antigen. The immunoprecipitate of HMSA-5 does not show any
positive reactivity with dopa staining of SDS-PAGE under reducing
conditions, indicating that HMSA-5 does not represent an active
tyrosinase molecule [42].
HMSA-6. HMSA-6 identifies four glycopeptides of 41, 22, 17, and
11 kDa in which two small polypeptide chains (22 and 17 kDa) are linked
to 11 -kDa protein by disulfide bonds; whereas, p 41 is the major protein
component in HMSA-6. Immunoprecipitation of pulse-chase – labeled
cells showed that p 41 is noted in 2 h and increases with time (24 h). Post-
translational and co-translational glycosylation analysis reveals a single
polypeptide component, 17 kDa, in the presence of glycosylation
inhibitors, tunicamycin, monensin, or castanospermine. Conversely, the
p 41 was synthesized in the presence of mannosidase II inhibitor,
swainsonine, and was immunoprecipitable as an endoglycosidase
H-resistant form. Analysis of tryptic glycopeptides indicated that the
p 41 differs from the 22-kDa molecule by the addition of oligosacchar-
ides (Fig 5).
SUMMARY AND CONCLUSION
The incidence and mortality rates of malignant melanoma continue to
rise dramatically throughout the world. In the United States, it is
estimated that one in 90 Americans will develop melanoma by the year
2000 [50,51]. Despite these alarming trends, it is equally disturbing to
know that there is no satisfactory treatment for advanced melanoma.
Thus, it is imperative that further research efforts be directed to
understanding the biology of this neoplasm [52,53]. In our laboratory,
we have concentrated our efforts in characterizing melanin synthesis and
expression of melanosomal proteins because they are uniquely expressed
to melanocyte differentation and transformation.
By studying the pathways of melanin synthesis and degradation, we
hope to be able to provide a more rational approach to the development
of specific and less toxic chemotherapeutic agents. In addition, the
accumulation and excretion of certain metabolites may serve as
diagnostic markers or monitoring indices for residual disease in advanced
melanoma. More specifically, we have demonstrated that 1) the synthesis
of pheomelanin is markedly increased in malignant melanoma and
dysplastic nevi; 2) high levels of metabolites of pheomelanin and
eumelanin can be detected in the blood and urine of patients with
metastatic melanoma; and 3) this release of melanin metabolites
correlates with tumor thickness and tumor load, including the extent of
metastases. The challenge remains to develop low-cost, readily available,
but highly sensitive and specific laboratory tests to improve the diagnosis
and monitoring of malignant melanoma.
Figure 4. Immunoelectron microscopic demonstration of MoAb HMSA-5 on
cultured melanoma cells, (a) Immunogold reactions with MoAb HMSA-5,
showing positive immunoprecipitates around melanosomes (arrows) at stages
I and II of maturation; (G) Golgj complex (magnification  13,000). (b) High-
power view of immunogold precipitates with MoAb HMSA-5 in stages I and II
melanosomes. Immunoprecipitates are seen around ‘‘vesiculoglobular
bodies’’ (arrow), which are associated with the surface or within the
melanosomes (magnification  23,000). (c) Control specimen for the MoAb
HMSA-5 immunoprecipitate. G361 human melanoma cultured cell line,
showing melanosomes at various developmental stages; N, nucleus
(magnification  15,500).
Figure 5. SDS-PAGE profiles of immunoprecipitates with MoAb HMSA-5 and
HMSA-6. G361 human melanoma cells (1  108) were tested with three
different concentrations of tunicamycin (TM) (0, 5 and 10 mg/ml, 5 h;
Boehringer Mannheim). They were metabolically radiola-beled with
35S-methionine (250mCi, specific activity; 100Ci/mmol; Amersham) and
immunoprecipitated with either MoAb HMSA-5 or HMSA-6. Lanes 1 and 2
denote the immunoprecipitates of SK NSH (human neuroblastoma cells, 108
cells) and S91 murine melanoma cells (108 cells) with MoAb HMSA-5,
respectively, showing the negative reactivities of human neuroblastoma cells
and murine melanoma cells. Lanes 3 and 4 denote SK NSH human
neuroblastoma cells and S91 murine melanoma cells, respectively, with
MoAB HMSA-6. The experimental conditions in lanes 3 and 4 are identical to
those of lanes 1 and 2, showing a strongly positive immunoprecipitate of
human neuroblastoma cells with MoAb HMSA-6. (C) control.
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Although the pathways of maturation and differentiation of the
melanocyte remain to be firmly established, much knowledge has been
derived from MoAb studies [54]. In its mature state, the melanocyte
contains melanosomes with many glycoproteins [5]. We have directed
our efforts to further characterization of the chemical structure and
function of these melanosomal antigens because they are important to
understanding melanocyte lineage, function, and malignant transforma-
tion [7]. MoAbs HMSA-1 and HMSA-2 stain positive for both dysplastic
and malignant melanocytes in the epidermis; however, they are negative
on epidermal melanocytes of benign common melanocytic nevi [40].
These data provide evidence for the concept that the dysplastic
melanocytes may share a biologic differentiation common to malignant
melanoma [55]. We also showed that MoAbs HMSA-3, HMSA-4, and
HMSA-6 are of great value in the differentiation of benign melanocytic
lesions from malignant melanoma. Finally, HMSA-6 may be a marker
for cells of neural-crest lineage. The question of whether the expression
or loss of some of these melanosomal antigens represents certain
stages of progression or types of melanomas remains to be resolved,
although our studies indicate that the combined staining patterns of
HMSA-1 –HMSA-4 may help to differentiate the subtypes of melanoma.
There are many potential applications of our studies. For example, the
original concept of the ‘‘magic bullet’’ for a drug-delivery system
programmed to localize to the sites of metastatic melanoma may regain
popularity once these tumor-specific antigens are better characterized. In
the past, MoAbs have been conjugated to conventional drugs, toxins, or
radionuclides; however, with the expanding field of tumor immunology,
this concept can be further refined by the coupling of cytokines, such as
tumor necrosis factor, interferon, or interleukin-2, to MoAbs. These
powerful cytokines have the capability to exert direct anti-tumor effects,
stimulate natural killer cells, or cytotoxic T cells to infiltrate the tumor site
and mediate tumor-specific lysis. This type of approach could
conceivably become an effective mode of therapy for widespread
melanoma. In conclusion, it is our long-term goal to apply knowledge
derived from these basic studies and to develop better strategies for the
treatment of advanced malignant melanoma.
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